Annual CFF
$178.96 M
+$58.65 M+48.75%
31 December 2023
Summary:
Keros Therapeutics annual cash flow from financing activities is currently $178.96 million, with the most recent change of +$58.65 million (+48.75%) on 31 December 2023. During the last 3 years, it has fallen by -$117.09 million (-39.55%). KROS annual CFF is now -39.55% below its all-time high of $296.04 million, reached on 31 December 2020.KROS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$155.94 M
+$152.41 M+4316.43%
30 September 2024
Summary:
Keros Therapeutics quarterly cash flow from financing activities is currently $155.94 million, with the most recent change of +$152.41 million (+4316.43%) on 30 September 2024. Over the past year, it has increased by +$155.66 million (+54809.86%). KROS quarterly CFF is now -0.55% below its all-time high of $156.80 million, reached on 31 March 2024.KROS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$385.53 M
+$155.66 M+67.72%
30 September 2024
Summary:
Keros Therapeutics TTM cash flow from financing activities is currently $385.53 million, with the most recent change of +$155.66 million (+67.72%) on 30 September 2024. Over the past year, it has increased by +$214.41 million (+125.30%). KROS TTM CFF is now at all-time high.KROS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KROS Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +48.8% | +10000.0% | +125.3% |
| 3 y3 years | -39.5% | +10000.0% | +174.9% |
| 5 y5 years | +1461.2% | +10000.0% | +10000.0% |
KROS Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -39.5% | +526.8% | -0.6% | >+9999.0% | at high | +1250.4% |
| 5 y | 5 years | -39.5% | >+9999.0% | -0.6% | >+9999.0% | at high | >+9999.0% |
| alltime | all time | -39.5% | >+9999.0% | -0.6% | at high |
Keros Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $155.94 M(+4316.4%) | $385.53 M(+67.7%) |
| June 2024 | - | $3.53 M(-97.7%) | $229.87 M(+0.8%) |
| Mar 2024 | - | $156.80 M(+126.4%) | $228.08 M(+27.5%) |
| Dec 2023 | $178.96 M(+48.7%) | $69.25 M(>+9900.0%) | $178.96 M(+4.6%) |
| Sept 2023 | - | $284.00 K(-83.7%) | $171.12 M(-22.0%) |
| June 2023 | - | $1.74 M(-98.4%) | $219.42 M(-3.7%) |
| Mar 2023 | - | $107.68 M(+75.3%) | $227.87 M(+89.4%) |
| Dec 2022 | $120.31 M(+321.4%) | $61.42 M(+26.4%) | $120.31 M(+37.8%) |
| Sept 2022 | - | $48.58 M(+376.7%) | $87.31 M(+125.2%) |
| June 2022 | - | $10.19 M(+8537.3%) | $38.76 M(+35.4%) |
| Mar 2022 | - | $118.00 K(-99.6%) | $28.63 M(+0.3%) |
| Dec 2021 | $28.55 M | $28.42 M(>+9900.0%) | $28.55 M(-79.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $35.00 K(-38.6%) | $140.25 M(+0.0%) |
| June 2021 | - | $57.00 K(+35.7%) | $140.22 M(-41.6%) |
| Mar 2021 | - | $42.00 K(-100.0%) | $240.29 M(-18.8%) |
| Dec 2020 | $296.04 M(>+9900.0%) | $140.12 M(>+9900.0%) | $296.04 M(+89.9%) |
| Sept 2020 | - | $9000.00(-100.0%) | $155.93 M(+0.0%) |
| June 2020 | - | $100.12 M(+79.5%) | $155.93 M(+179.4%) |
| Mar 2020 | - | $55.79 M(>+9900.0%) | $55.81 M(>+9900.0%) |
| Dec 2019 | $14.00 K(-99.9%) | $4000.00(-33.3%) | $14.00 K(+40.0%) |
| Sept 2019 | - | $6000.00(+50.0%) | $10.00 K(+150.0%) |
| June 2019 | - | $4000.00(>+9900.0%) | $4000.00(>+9900.0%) |
| Mar 2019 | - | $0.00 | $0.00 |
| Dec 2018 | $11.46 M | - | - |
FAQ
- What is Keros Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Keros Therapeutics?
- What is Keros Therapeutics annual CFF year-on-year change?
- What is Keros Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Keros Therapeutics?
- What is Keros Therapeutics quarterly CFF year-on-year change?
- What is Keros Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Keros Therapeutics?
- What is Keros Therapeutics TTM CFF year-on-year change?
What is Keros Therapeutics annual cash flow from financing activities?
The current annual CFF of KROS is $178.96 M
What is the all time high annual CFF for Keros Therapeutics?
Keros Therapeutics all-time high annual cash flow from financing activities is $296.04 M
What is Keros Therapeutics annual CFF year-on-year change?
Over the past year, KROS annual cash flow from financing activities has changed by +$58.65 M (+48.75%)
What is Keros Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of KROS is $155.94 M
What is the all time high quarterly CFF for Keros Therapeutics?
Keros Therapeutics all-time high quarterly cash flow from financing activities is $156.80 M
What is Keros Therapeutics quarterly CFF year-on-year change?
Over the past year, KROS quarterly cash flow from financing activities has changed by +$155.66 M (+54809.86%)
What is Keros Therapeutics TTM cash flow from financing activities?
The current TTM CFF of KROS is $385.53 M
What is the all time high TTM CFF for Keros Therapeutics?
Keros Therapeutics all-time high TTM cash flow from financing activities is $385.53 M
What is Keros Therapeutics TTM CFF year-on-year change?
Over the past year, KROS TTM cash flow from financing activities has changed by +$214.41 M (+125.30%)